Literature DB >> 12687335

A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.

Y Park1, B D Freedman, E J Lee, S Park, J L Jameson.   

Abstract

AIMS/HYPOTHESIS: PPARgamma, a member of the nuclear hormone receptor family of transcription factors, plays a key role in adipocyte differentiation and insulin sensitivity. The aim of this study was to identify a potential dominant negative murine PPARgamma mutant and to characterize the in vitro functional properties of this mutant.
METHODS: In vitro transient transfections and mammalian two-hybrid assays in TSA201 cells were used to characterize the transcriptional activity of the L466A mutant and to study the molecular interaction of transcriptional cofactors with the L466A mutant in an attempt to elucidate the mechanism of its dominant negative activity. Adenoviral constructs expressing PPARgamma wild-type (AdWT) or the L466A mutant (AdL466A) were infected into the murine 3T3-L1 cell line to study the mutant's effect on adipogenesis.
RESULTS: The L466A mutant alone is transcriptionally defective. However, it retains DNA binding and inhibits the ligand-dependent and -independent activity of the wild-type receptor, consistent with dominant negative properties. In mammalian two-hybrid studies, the L466A mutant does not bind nuclear receptor coactivators. However, it more avidly recruits corepressors due to enhanced binding to the corepressor ID1 domain, leading to pronounced transcriptional repression. The AdL466A mutant inhibits adipogenesis induced by either a differentiation cocktail or by thiazolidinedione ligand. AdL466A infection also blocked the upregulation of the adipocyte marker genes aP2 and adipsin.
CONCLUSION: We conclude that the L466A PPARgamma mutant possesses potent dominant negative activity based on preferential corepressor recruitment and it inhibits adipogenesis and the expression of adipocyte-specific genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687335     DOI: 10.1007/s00125-003-1037-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  59 in total

1.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway.

Authors:  Evan D Rosen; Chung-Hsin Hsu; Xinzhong Wang; Shuichi Sakai; Mason W Freeman; Frank J Gonzalez; Bruce M Spiegelman
Journal:  Genes Dev       Date:  2002-01-01       Impact factor: 11.361

3.  A novel role for helix 12 of retinoid X receptor in regulating repression.

Authors:  J Zhang; X Hu; M A Lazar
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release.

Authors:  B C Lin; S H Hong; S Krig; S M Yoh; M L Privalsky
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

5.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

6.  Pulse time and agarose concentration affect the electrophoretic mobility of cccDNA during PFGE and FIGE [corrected].

Authors:  B W Sobral; A G Atherly
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

7.  A canonical structure for the ligand-binding domain of nuclear receptors.

Authors:  J M Wurtz; W Bourguet; J P Renaud; V Vivat; P Chambon; D Moras; H Gronemeyer
Journal:  Nat Struct Biol       Date:  1996-01

8.  Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.

Authors:  L Nagy; H Y Kao; D Chakravarti; R J Lin; C A Hassig; D E Ayer; S L Schreiber; R M Evans
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

9.  p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively.

Authors:  L Gelman; G Zhou; L Fajas; E Raspé; J C Fruchart; J Auwerx
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  15 in total

1.  Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency.

Authors:  Philippe M Campeau; Olga Astapova; Rebecca Martins; Jean Bergeron; Patrick Couture; Robert A Hegele; Todd Leff; Claude Gagné
Journal:  J Lipid Res       Date:  2012-07-02       Impact factor: 5.922

2.  Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.

Authors:  Youngkyu Park; Evelyn T Maizels; Zachary J Feiger; Hena Alam; Carl A Peters; Teresa K Woodruff; Terry G Unterman; Eun Jig Lee; J Larry Jameson; Mary Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

3.  Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.

Authors:  Avani A Pendse; Lance A Johnson; Hyung-Suk Kim; Marcus McNair; C Taylor Nipp; Carolyn Wilhelm; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-26       Impact factor: 8.311

4.  Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring.

Authors:  A E Kuriyan; G M Lehmann; A A Kulkarni; C F Woeller; S E Feldon; H B Hindman; P J Sime; K R Huxlin; R P Phipps
Journal:  Exp Eye Res       Date:  2011-12-08       Impact factor: 3.467

Review 5.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

6.  PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.

Authors:  Jun Wei; Asish K Ghosh; Jennifer L Sargent; Kazuhiro Komura; Minghua Wu; Qi-Quan Huang; Manu Jain; Michael L Whitfield; Carol Feghali-Bostwick; John Varga
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

7.  Relaxin signaling activates peroxisome proliferator-activated receptor gamma.

Authors:  Sudhir Singh; Robert G Bennett
Journal:  Mol Cell Endocrinol       Date:  2009-08-25       Impact factor: 4.102

8.  Neuronal microtubule-associated protein 2D is a dual a-kinase anchoring protein expressed in rat ovarian granulosa cells.

Authors:  Lisa M Salvador; Maxfield P Flynn; Jesús Avila; Scott Reierstad; Evelyn T Maizels; Hena Alam; Youngkyu Park; John D Scott; Daniel W Carr; Mary Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

9.  Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers.

Authors:  Shanika P Samarasinghe; Maria M Sutanto; Arpad M Danos; Daniel N Johnson; Matthew J Brady; Ronald N Cohen
Journal:  Obesity (Silver Spring)       Date:  2009-01-22       Impact factor: 5.002

10.  Leptin Antagonizes Peroxisome Proliferator-Activated Receptor-γ Signaling in Growth Plate Chondrocytes.

Authors:  Lai Wang; Yvonne Y Shao; R Tracy Ballock
Journal:  PPAR Res       Date:  2012-09-13       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.